<VariationArchive VariationID="1459687" VariationName="NC_000018.9:g.(?_43502287)_(43505888_?)del" VariationType="Deletion" Accession="VCV001459687" Version="6" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1484875" VariationID="1459687">
      <GeneList>
        <Gene Symbol="EPG5" FullName="ectopic P-granules 5 autophagy tethering factor" GeneID="57724" HGNC_ID="HGNC:29331" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>18q12.3-21.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="18" Accession="NC_000018.10" start="45800581" stop="45967329" display_start="45800581" display_stop="45967329" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="18" Accession="NC_000018.9" start="43427573" stop="43547304" display_start="43427573" display_stop="43547304" Strand="-" />
          </Location>
          <OMIM>615068</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000018.9:g.(?_43502287)_(43505888_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>18q21.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="18" Accession="NC_000018.9" innerStart="43502287" innerStop="43505888" display_start="43502287" display_stop="43505888" variantLength="3602" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000018.9" sequenceAccession="NC_000018" sequenceVersion="9" change="g.(?_43502287)_(43505888_?)del" Assembly="GRCh37">
            <Expression>NC_000018.9:g.(?_43502287)_(43505888_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000018.9:g.(?_43502287)_(43505888_?)del AND Vici syndrome" Accession="RCV001982873" Version="6">
        <ClassifiedConditionList TraitSetID="9271">
          <ClassifiedCondition DB="MedGen" ID="C1855772">Vici syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-12-02" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">23222957</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23674064</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="9271" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2298" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Absent corpus callosum cataract immunodeficiency</ElementValue>
                <XRef ID="Absent+Corpus+Callosum+Cataract+Immunodeficiency/81" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Immunodeficiency with cleft lip/palate, cataract, hypopigmentation and absent corpus callosum</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Vici syndrome</ElementValue>
                <XRef ID="MONDO:0009452" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">VICIS</ElementValue>
                <XRef Type="MIM" ID="242840" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">With the current widespread use of multigene panels and comprehensive genomic testing, it has become apparent that the phenotypic spectrum of EPG5-related disorder represents a continuum. At the most severe end of the spectrum is classic Vici syndrome (defined as a neurodevelopmental disorder with multisystem involvement characterized by the combination of agenesis of the corpus callosum, cataracts, hypopigmentation, cardiomyopathy, combined immunodeficiency, microcephaly, and failure to thrive); at the milder end of the spectrum are attenuated neurodevelopmental phenotypes with variable multisystem involvement. Median survival in classic Vici syndrome appears to be 24 months, with only 10% of children surviving longer than age five years; the most common causes of death are respiratory infections as a result of primary immunodeficiency and/or cardiac insufficiency resulting from progressive cardiac failure. No data are available on life span in individuals at the milder end of the spectrum.</Attribute>
                <XRef ID="NBK584989" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">EPG5-Related Disorder</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">EPG5-Related Vici Syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="448" />
                <XRef ID="448" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">EPG5 Deficiency</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">36228046</ID>
                <ID Source="BookShelf">NBK584989</ID>
              </Citation>
              <XRef ID="1493" DB="Orphanet" />
              <XRef ID="C1855772" DB="MedGen" />
              <XRef ID="MONDO:0009452" DB="MONDO" />
              <XRef Type="MIM" ID="242840" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4263451" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_020964.2_18_Deletion (exons 14-16)|MedGen:C1855772" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002238827" DateUpdated="2024-06-09" DateCreated="2022-03-28" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23222957</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23674064</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with EPG5-related conditions. This variant is a gross deletion of the genomic region encompassing exon(s) 14-16 of the EPG5 gene. This deletion is out-of-frame, and is expected to create a premature termination codon and result in an absent or disrupted protein product. Loss-of-function variants in EPG5 are known to be pathogenic (PMID: 23222957, 23674064).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="EPG5" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000018.9:g.(?_43502287)_(43505888_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1855772" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4263451" TraitType="Disease" MappingType="XRef" MappingValue="C1855772" MappingRef="MedGen">
        <MedGen CUI="C1855772" Name="Vici syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

